On Thursday, Piramal Pharma announced their financial results for the third quarter of the fiscal year which ended on December 31, 2022. The company reported a consolidated net loss of

The demerger was to transform the multi-sector conglomerate structure of the company into two separate sector-focused – financial services and pharmaceuticals — listed entities and command leadership positions in those